Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 3/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 5/20 | 0.41 |
| ▸ | ADRB3 | P13945 | 5/20 | 0.40 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.39 |
| ▸ | PDE4A | P27815 | 2/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.38 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | AR | P10275 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | ESRRA | P11474 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2454673 | 1.00 | CYP19A1 (0.43) | CYP19A1TRPV1ADRB3ADRB2PDE4A | |
| SCHEMBL14090675 | 1.00 | CYP19A1 (0.43) | CYP19A1TRPV1ADRB3ADRB2PDE4A | |
| SCHEMBL8817465 | 0.90 | CYP19A1 (0.43) | CYP19A1TRPV1ADRB3ADRB2PDE4A | |
| SCHEMBL273843 | 0.87 | MAPT (0.41) | ADRB2HPGDRAB9A | |
| SCHEMBL1205616 | 0.87 | MAPT (0.41) | ADRB2HPGDRAB9A | |
| SCHEMBL7605339 | 0.86 | CYP19A1 (0.44) | CYP19A1TRPV1ADRB3PDE4APDE4B | |
| SCHEMBL7605348 | 0.86 | CYP19A1 (0.44) | CYP19A1TRPV1ADRB3PDE4APDE4B | |
| SCHEMBL14643022 | 0.86 | CYP19A1 (0.39) | CYP19A1TRPV1ADRB3ADRB2PDE4A | |
| SCHEMBL14704368 | 0.84 | TRPV1 (0.40) | CYP19A1TRPV1NPC1RAB9AESRRA | |
| SCHEMBL12305648 | 0.84 | ADRB2 (0.44) | CYP19A1TRPV1ADRB3ADRB2PDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107108502-A | having beta2Biphenyl derivatives with receptor agonism and M receptor antagonistic activity and application thereof in medicine | 四川海思科制药有限公司 | 2017-08-29 | — | — | CN | disclosed |
| WO-2016180349-A1 | BIPHENYL DERIVATIVE HAVING BETA2 RECEPTOR EXCITEMENT AND M RECEPTOR ANTAGONISTIC ACTIVITIES AND APPLICATION THEREFOF IN MEDICAMENT | 四川海思科制药有限公司 | 2016-11-17 | — | — | WO | disclosed |
| EP-2764866-A1 | Inhibitors of nedd8-activating enzyme | IP Gesellschaft für Management mbH (DE) | 2014-08-13 | — | — | EP | disclosed |
| US-8013019-B2 | Sulfonamide derivatives for the treatment of diseases | PFIZER INC (US) | 2011-09-06 | — | — | US | disclosed |
| US-8013019-B2 | Sulfonamide derivatives for the treatment of diseases | PFIZER INC (US) | 2011-09-06 | — | — | US | disclosed |
| US-20100273758-A1 | Sulfonamide Derivatives For The Treatment Of Diseases | BROWN ALAN DANIEL | 2010-10-28 | — | — | US | disclosed |
| US-20100273758-A1 | Sulfonamide Derivatives For The Treatment Of Diseases | BROWN ALAN DANIEL | 2010-10-28 | — | — | US | disclosed |
| US-7767715-B2 | Sulfonamide derivatives for the treatment of diseases | PFIZER INC (US) | 2010-08-03 | — | — | US | disclosed |
| US-7767715-B2 | Sulfonamide derivatives for the treatment of diseases | PFIZER INC (US) | 2010-08-03 | — | — | US | disclosed |
| US-7612084-B2 | Amine derivatives for the treatment of asthma and COPD | PFIZER INC (US) | 2009-11-03 | — | — | US | disclosed |
| US-7351742-B2 | Sulfonamide derivatives for the treatment of diseases | PFIZER INC. (US) | 2008-04-01 | — | — | US | disclosed |
| US-20070265303-A1 | Amine derivatives | PFIZER LIMITED | 2007-11-15 | — | — | US | disclosed |
| EP-1708991-B1 | SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES | PFIZER LTD (GB) | 2007-10-17 | — | — | EP | disclosed |
| WO-2007107828-A2 | AMINE DERIVATIVES | PFIZER LIMITED (GB) | 2007-09-27 | — | — | WO | disclosed |
| EP-1708992-B1 | SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES | PFIZER LTD (GB) | 2007-08-08 | — | — | EP | disclosed |
| US-7244766-B2 | Sulfonamide derivatives for the treatment of diseases | PFIZER INC (US) | 2007-07-17 | — | — | US | disclosed |
| US-7244766-B2 | Sulfonamide derivatives for the treatment of diseases | PFIZER INC (US) | 2007-07-17 | — | — | US | disclosed |
| WO-2005080313-A9 | SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES | PFIZER LTD (GB) | 2006-08-31 | — | — | WO | disclosed |
| US-20050182091-A1 | For therapy of asthma or chronic obstructive pulmonary disease (COPD) in a mammal | PFIZER INC. | 2005-08-18 | — | — | US | disclosed |
| US-20050171147-A1 | Sulfonamide derivatives for the treatment of diseases | PFIZER INC. | 2005-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273758-A1 | Sulfonamide Derivatives For The Treatment Of Diseases | SULT2A1, STS, SULT1A1 | CYP19A1 248/4885TRPV1 88/4885ADRB3 2520/4885 |
| US-20050182091-A1 | For therapy of asthma or chronic obstructive pulmonary disease (COPD) in a mammal | LTC4S, LTB4R2, LTB4R | CYP19A1 214/4885TRPV1 1356/4885ADRB3 107/4885 |
| US-20050171147-A1 | Sulfonamide derivatives for the treatment of diseases | SULT2A1, STS, SULT1A1 | CYP19A1 248/4885TRPV1 88/4885ADRB3 2520/4885 |
| US-20070265303-A1 | Amine derivatives | HNMT, HRH4, CMA1 | CYP19A1 86/4885TRPV1 506/4885ADRB3 108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.